Holen Sie sich die Stockscreener-App
10.23
0.54%
0.0445
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress - simplywall.st
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Trading Action: Should I set a stop loss on Zevra Therapeutics IncEarnings Beat & Daily Profit Focused Screening - baoquankhu1.vn
Zevra Therapeutics appoints Justin Renz as CFO - MSN
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance - Yahoo Finance
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C - Zacks Investment Research
Zevra at Citizens Life Sciences: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
ZVRA: MIPLYFFA drives rare disease growth with strong revenue, global expansion, and pipeline progress - TradingView
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge? - Yahoo Finance
Brokers Offer Predictions for ZVRA Q3 Earnings - MarketBeat
Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case - simplywall.st
Zevra Therapeutics Faces Partnership Hurdles That Could Delay Drug Development and Pressure Financing - TipRanks
Why Is Zevra Therapeutics Stock Trading Higher Today? - Bitget
Why Zevra Therapeutics stock zoomed 21% higher today - MSN
Why Zevra Therapeutics Stock Zoomed 21% Higher Today - Yahoo Finance
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpHere's What Happened - MarketBeat
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model (NASDAQ:ZVRA) - Seeking Alpha
GeneDx Holdings Corp. to Launch Genetic Testing Program with Zevra Therapeutics, Inc. to Support Patients with Suspected Niemann-Pick Disease Type C - marketscreener.com
Zevra Therapeutics partners with GeneDx to launch genetic testing for NPC in U.S. - Traders Union
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C - Business Wire
Guggenheim raises Zevra Therapeutics stock price target to $23 By Investing.com - Investing.com Australia
US Premarket Movers: BioNTech, Kohl’s, Teladoc, Vertex, Zevra - Bloomberg.com
Guggenheim raises Zevra Therapeutics stock price target to $23 - Investing.com
Zevra Therapeutics price target raised to $23 from $22 at Guggenheim - TipRanks
Zevra Therapeutics Stock Pre-Market (+17%): Blowout Q4 Earnings & Revenue Beat - Trefis
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Profit Swing, MIPLYFFA Uptake and New CFO Might Change The Case For Investing In Zevra Therapeutics (ZVRA) - simplywall.st
Zevra Therapeutics Stock Pre-Market (+17%): Reports Massive Q4 EPS Beat - Trefis
Zevra Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Zevra Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
Earnings call transcript: Zevra Therapeutics Q4 2025 earnings beat forecasts By Investing.com - Investing.com Australia
ZVRA Stock Soars On Upbeat Q4 Results, Optimism For EMA Approval Of Niemann-Pick Disease Treatment - Asianet Newsable
Earnings call transcript: Zevra Therapeutics Q4 2025 earnings beat forecasts - Investing.com
ZVRA Reports Strong Q4 Revenue and Strategic Growth Plans - GuruFocus
Zevra Therapeutics Q4 Earnings Call Highlights - MarketBeat
Zevra Therapeutics earnings beat by $0.14, revenue topped estimates - Investing.com Canada
Zevra Therapeutics Q4 2025 Earnings: $12.2M Net Income, Revenue Beats ForecastsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Zevra Therapeutics reports Q4 EPS 20c, consensus 5c - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zevra Therapeutics: Fourth Quarter Earnings Overview - Bitget
Zevra 2025 net income hits $83M on $106M revenue - National Today
Zevra Therapeutics Appoints Justin Renz as New CFO - TipRanks
ZVRA Exceeds Revenue Expectations and Expands Boston Headquarters - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Releases Earnings Results, Beats Estimates By $0.14 EPS - MarketBeat
Zevra Therapeutics Q4 Swings to Profit, Revenue Rises - marketscreener.com
Zevra Therapeutics beats FY 2025 revenue expectations - TradingView
Zevra Therapeutics Reports Q4 2025 Financial Results with 31% Revenue Growth and Announces Upcoming Conference Call - Quiver Quantitative
Zevra Therapeutics Q4 Earnings Report: What Investors Need to Know - Benzinga
From $105.5M net loss to $83.2M net income: Zevra 2025 results - Stock Titan
Zevra Therapeutics, Inc. Q4 2025 earnings preview - MSN
Zevra Therapeutics (ZVRA) Anticipates Q4 Earnings Report - GuruFocus
New Zevra CFO Appointment Highlights Rare Disease Focus And Valuation Gap - Yahoo Finance
Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Gains And Rare Disease Growth Hopes - Yahoo Finance
Momentum Shift: What is the next catalyst for Zevra Therapeutics IncTrade Ideas & Comprehensive Market Scan Reports - baoquankhu1.vn
Zevra Therapeutics, Inc. Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Uncovering Potential: Zevra Therapeutics's Earnings Preview - Benzinga
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer - Sahm
Zevra Therapeutics Appoints New CFO - Intellectia AI
Zevra Therapeutics Names Justin Renz CFO - marketscreener.com
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):